FIELD: medicine.
SUBSTANCE: present invention refers to prognostic analysis, as well as to a method for applying it for determining a probability of producing a therapeutic response in the affected cells or tissues on treating a disease having an aethiology related to excessive cell proliferation with using cardiac glycoside. The method for prediction consists in determining the relation of Na, K-adenosine triphosphatase α-subunit isoforms in the affected cells or tissues. The above method can be used for the prediction of individual's cancer or tumour sensitivity to the therapeutic treatment with cardiac glycoside.
EFFECT: predicted method can be applied in a method of treating a disease or a disorder having an aethiology related to excess cell proliferation with using the composition containing cardiac glycoside.
59 cl, 9 tbl, 27 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| KIT FOR DETECTING PROBABILITY OF THERAPEUTIC RESPONSE TO ANTI-CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE | 2008 |
|
RU2571687C2 |
| METHOD OF TREATING NEUROLOGICAL DISORDERS WITH CARDIAC GLYCOSIDES | 2011 |
|
RU2582223C2 |
| METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH CARDIAC GLYCOSIDS | 2011 |
|
RU2674679C2 |
| METHOD FOR CELL PROTECTION AGAINST HYPOXIC INJURY BY GLUTATHIONYLATION OF Na, K-ADENOSINE TRIPHOSPHATASE CATALYTIC SUBUNIT | 2013 |
|
RU2544958C2 |
| METHOD OF IN VITRO DETERMINATION OF PROGNOSIS OF DISEASE DEVELOPMENT IN PATIENT WITH CANCER AND METHOD OF IN VITRO MONITORING EFFECT OF THERAPY ADMINISTERED TO PATIENT WITH CANCER | 2006 |
|
RU2434946C2 |
| SUPERCRITICAL LIQUID EXTRACT CONTAINING CARDIAC GLYCOSIDE | 2006 |
|
RU2398591C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
| ANTIFIBROLYTIC MEANS | 2016 |
|
RU2621299C1 |
| ANTIFIBROLYTIC MEANS | 2016 |
|
RU2621163C1 |
| HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
